Cellectar Biosciences, Inc. Logo

Cellectar Biosciences, Inc.

Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.

CLRB | US

Overview

Corporate Details

ISIN(s):
US15117F8077
LEI:
Country:
United States of America
Address:
100 CAMPUS DRIVE, 7932 FLORHAM PARK

Description

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectar Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectar Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellectar Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Double Bond Pharmaceutical International AB Logo
Redevelops drugs with targeted delivery to improve safety and efficacy.
Sweden
DBP B
DR REDDYS LABORATORIES LTD Logo
An integrated global pharmaceutical company providing affordable and innovative medicines.
United States of America
RDY
Drugs Made In America Acquisition Corp. Logo
A SPAC targeting U.S.-based pharmaceutical and biopharmaceutical companies.
United States of America
DMAA
Develops, manufactures, and commercializes radiopharmaceuticals for diagnosis and treatment.
South Korea
176750
Dx & Vx Co., Ltd. Logo
A bio-healthcare company specializing in diagnostics and mRNA vaccine development.
South Korea
180400
DYNAVAX TECHNOLOGIES CORP Logo
Biopharmaceutical company developing and commercializing vaccines and adjuvant technology.
United States of America
DVAX
Dyne Therapeutics, Inc. Logo
Develops targeted therapies for genetically driven neuromuscular diseases.
United States of America
DYN
Manufactures veterinary pharmaceuticals and develops premium pet food.
South Korea
044960
Eckert & Ziegler Strahlen- und Medizintechnik AG Logo
A global provider of isotope technology for medical, scientific, and industrial use.
Germany
EUZ
ECO ANIMAL HEALTH GROUP PLC Logo
Develops and markets pharmaceuticals and biologicals for pig and poultry health.
United Kingdom
EAH

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.